{"id":"cytosin-arabinosid","safety":{"commonSideEffects":[{"rate":"70-90","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"60-80","effect":"Nausea and vomiting"},{"rate":"40-60","effect":"Mucositis"},{"rate":"10-20","effect":"Hepatotoxicity"},{"rate":"5-15","effect":"Neurotoxicity (at high doses)"},{"rate":"30-50","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL5433746","moleculeType":null,"molecularWeight":"337.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cytarabine is a cytidine analog that is phosphorylated intracellularly and incorporated into DNA, causing chain termination and inhibition of DNA polymerase. This mechanism is particularly effective against rapidly dividing cells, making it useful in hematologic malignancies. It is cell cycle-specific, acting primarily during the S phase.","oneSentence":"Cytarabine (Cytosin-Arabinosid) is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA during the S phase of the cell cycle, leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:19.147Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Chronic myeloid leukemia (CML) in blast phase"},{"name":"Lymphoma"}]},"trialDetails":[{"nctId":"NCT00146120","phase":"PHASE3","title":"Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result","status":"COMPLETED","sponsor":"University of Ulm","startDate":"1998-05","conditions":"Acute Myeloid Leukemia","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cytosin-Arabinosid","genericName":"Cytosin-Arabinosid","companyName":"University of Ulm","companyId":"university-of-ulm","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cytarabine (Cytosin-Arabinosid) is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA during the S phase of the cell cycle, leading to cell death. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast phase.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}